BioSpace News Archive

Translate Bio, a clinical-stage messenger RNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, announced financial results and business highlights for the fourth quarter and full year ended December 31, 2019.

Ra Medical Systems, Inc., a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces the appointment of Will McGuire as Chief Executive Officer and a member of the company’s Board of Directors, effective March 30, 2020.

NextCure, Inc. reported fourth quarter and full year 2019 financial results and provided a business update.

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, will release its financial results for the fourth quarter and full year ended December 31, 2019, before the market open on Monday, March 16, 2020, and host a webcast and conference call at 8:30am ET.

Quest Diagnostics, the world’s leading provider of diagnostic information services, announced that its Board of Directors has elected Mr. Wright L. Lassiter III to serve as a director.

ERYTECH Pharma announced that it will host its fourth quarter and full year 2019 conference call and webcast on Tuesday, March 17, 2020, at 1:30 PM CET/8:30 AM EST to discuss operational highlights.

Launching a two-pronged attack on cancer’s ability to safeguard its DNA could offer an effective new way of treating the disease, a new study reports.

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, publishes its financial results for 2019 and provides an update on its product portfolio.

AbCellera and Lilly will select from 500+ unique antibodies isolated from one of the first U.S. patients who recovered from COVID-19 to create antibody therapeutics for treatment and prevention of COVID-19 [12-March-2020] VANCOUVER, British Columbia and INDIANAPOLIS , March 12, 2020 /PRNewswire/ -- AbCellera and Eli Lilly and Company (NYSE: LLY) announced today they

China’s pharmaceutical industry is rapidly switching from the “quantity increase” to the “quality improvement”, developing from a “generic drug power” to an “innovative drug power”.